64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

Colorectal Cancer Clinical Trial

— PHANTOM  

Official title:

A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) in Patients With Sarcoma or Gastrointestinal Tract Cancer (PHANTOM Trial)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06298916
• Other study ID #: FAPi-1301
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: May 2024
• Est. completion date: April 2026

Study information

• Verified date: March 2024
• Source: Lantheus Medical Imaging
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity and mass dose) and imaging time window of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) and to compare its imaging biodistribution with FAP expression by immunohistochemistry (IHC) in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).

Description:

Part 1 will determine the biodistribution, dosimetry, optimal dose (radioactivity and mass dose) and imaging time window of 64Cu-LNTH-1363S in 12 evaluable patients with supposed FAP-expressing solid tumors (metastatic sarcomas). Two 64Cu-LNTH-1363S mass doses of ~50 μg and ~90 μg will be studied. Six patients will receive 8 ± 1 millicurie (mCi) (~50 μg mass dose), followed by another 6 patients will receive 8 ± 1 mCi (~90 μg mass dose). Two additional radioactivity (6 and 4 mCi) doses will be simulated by reprocessing raw data from each patient's PET scans.

This study does not involve randomization for dose groups. It will commence with the lower dose group (~50 μg mass dose). After enrolling 6 evaluable patients in this dose group, recruitment for the next dose group (~90 μg mass dose) will begin and conclude upon enrolling 6 evaluable patients. Subsequently, the images will undergo analysis by blinded central readers.

Part 1 of the study will last approximately 3 weeks for each patient and includes a Screening Period (up to 14 days), a 1-day Intervention Period, and a Safety Follow-up Period (7 days post dose).

Part 2 will evaluate 64Cu-LNTH-1363S imaging correlation with FAP expression measured by IHC (SUVmax and SUVmean vs IHC score) in 20 evaluable patients with non-metastatic, operable, supposed FAP-expressing solid tumors (sarcomas, esophageal, gastric, pancreatic, colorectal) planned for surgery within 60 days (from study imaging). If the optimal radioactivity determined from Part 1 is less than 8 ± 1 mCi, the first 6 patients in Part 2 will be used to validate this optimal radioactivity. This mean the image quality scores of the first 6 patients will need to be calculated. If the sum of the average image quality scores of the 6 patients is higher or equal to 10.5, then the lower optimal radioactivity determined in Part 1 will be used for the remaining 14 patients, otherwise the remaining 14 patients in Part 2 will be injected with 8 ± 1 mCi of 64Cu-LNTH-1363S. Part 2 of the study will last approximately 10 to 11 weeks for each patient and includes: a Screening Period (up to 14 days), a 1-day Intervention Period, a 1-day Safety Follow-up Period (Day 2), and a Scheduled Surgery: IHC Sample Collection Period (from Day 2 to Day 60).

Both Part 1 and Part 2 of the study will also monitor cardiac safety by detecting changes in HR, T wave, ST segment and other ECG parameters and look for signals suggesting a concentration-response relationship of 64Cu-LNTH-1363S for QT and corrected QT interval (QTc) prolongation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 32
• Est. completion date: April 2026
• Est. primary completion date: November 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: Part 1

Patients are eligible to be included in the study only if all of the following criteria apply:

1. Patient must be = 18 years of age and must have provided written informed consent.

2. Patients with suspected FAP-expressing metastatic sarcoma.

3. Patients must have histological, pathological, and/or cytological confirmation of a metastatic sarcoma (e.g., undifferentiated pleomorphic sarcoma, liposarcoma, Leiomyosarcoma, myxofibrosarcoma, solitary fibrous tumor, Ewing's sarcoma, synovial sarcoma, sarcoma not otherwise specified, osteosarcoma).

4. Patients must be willing to consent to provide sufficient and adequate archived tumor tissue samples (formalin fixed, paraffin embedded sample), preferably from a biopsy of a tumor lesion obtained either at the time of or after the diagnosis of disease; if archival tissue sample is unavailable, a new biopsy should be performed on the most accessible lesion(s) to obtain the tumor tissue sample.

5. Adequate renal function as determined by a calculated creatinine clearance = 60 mL/min (Cockcroft Gault equation).

6. Women of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin (ß-hCG) test and must not be breastfeeding. WOCBP must agree to use a highly effective method of contraception during the study and for 28 days after the last injection of the study drug.

7. Male subjects who are able to father a child must agree to avoid impregnating a partner, to adhere to a highly effective method of contraception and to not donate sperm during the study and for 28 days after the last injection of the study drug.

Inclusion Criteria: Part 2

1. Patients must be = 18 years of age and must have provided written informed consent.

2. Patients must have histological, pathological, and/or cytological confirmation of a sarcoma or GIT cancers e.g., esophageal, gastric, pancreatic, colorectal cancer.

3. Patients must have suspected FAP expressing sarcoma or GIT cancers and planned for surgery within 60 days (from study imaging).

4. Patients must be willing to consent to provide sufficient and adequate tumor tissue samples (formalin fixed, paraffin embedded sample), from their planned surgery after participating in study imaging.

5. Adequate renal function as determined by a calculated creatinine clearance = 60 mL/min (Cockcroft Gault equation).

6. Women of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin (ß-hCG) test and must not be breastfeeding. WOCBP must agree to use a highly effective method of contraception during the study and for 28 days after the last injection of the study drug.

7. Male subjects who are able to father a child must agree to avoid impregnating a partner, to adhere to a highly effective method of contraception and to not donate sperm during the study and for 28 days after the last injection of the study drug.

Exclusion Criteria: Part 1

Patients are excluded from the study if any of the following criteria apply:

1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the investigator to be unsuitable for participation.

2. Known pregnancy or breastfeeding.

3. Any PET scan done within 10 physical half-lives of the PET agent prior to receiving study intervention.

4. They are participating as patients in another clinical study with an Investigational Product or another systemic therapy administered in the last 3 weeks.

5. Has undergone or plans to undergo PET or single-photon emission computerized tomography (SPECT) imaging with any other FAPi imaging agent within 6 months prior to or after participating in this trial.

6. History of QT/QTc interval prolongation, a marked baseline QT/QTc interval prolongation (e.g., repeated demonstration of a QTc interval, calculated with Fridericia's correction, > 450 milliseconds) or taking medications known to cause QT/QTc prolongation.

7. A history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome).

8. Have history of QT prolongation or is taking a medication known to cause QT prolongation.

Exclusion Criteria: Part 2

1. Patients who have received or are scheduled to receive neoadjuvant anti-cancer therapy.

2. Evidence of metastatic or advanced, inoperable disease.

3. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the investigator to be unsuitable for participation.

4. Known pregnancy or breastfeeding.

5. Any PET scan done within 10 physical half-lives of the PET agent prior to receiving study intervention.

6. They are participating as patients in another clinical study with an Investigational Product or another systemic therapy administered in the last 3 weeks.

7. Has undergone or plans to undergo PET or SPECT imaging with any other FAPi imaging agent within 6 months prior to or after participating in this trial.

8. History of QT/QTc interval prolongation, a marked baseline QT/QTc interval prolongation (e.g., repeated demonstration of a QTc interval, calculated with Fridericia's correction, > 450 milliseconds) or taking medications known to cause QT/QTc prolongation.

9. A history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome)

10. Have history of QT prolongation or is taking a medication known to cause QT prolongation.

Related Conditions & MeSH terms

• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer
• Gastrointestinal Neoplasms
• Metastatic Sarcoma
• Pancreatic Cancer
• Sarcoma

Intervention

Combination Product:
• 64Cu-LNTH-1363S
64Cu-LNTH-1363S, is a highly selective, high affinity FAP inhibitor (FAPi) that is radiolabeled with Copper-64 (64Cu) for PET/CT Imaging,

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Lantheus Medical Imaging

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory Part 1 and Part 2	Develop an AI system for detecting and characterizing cancer lesion(s) expressing FAP using 64Cu-LNTH-1363S, through Correlation between automated measurement of physiological uptake of 64Cu-LNTH-1363S with manual measurement results; and through the determination of the detection rate of possible site of cancer lesion(s) with 64Cu-LNTH-1363S using an AI enabled reading system when compared to central reader assessments.; Part 2: Estimation of total tumor burden using an AI enabled reading system.	From post study intervention administration imaging in each patient (0.5 hour ± 10 minutes, 1 hour ±10 minutes, 2 hours ± 15 minutes, 4 to 6 hours, and 24 hours ± 4 hours in Part 1 and 2 timepoints in Part 2) to the end of the study].
Primary	Primary Part 1 Biodistribution of 64Cu-LNTH-1363S	Time Activity Curves (TACs) describing percentage of the injected activity versus time will be derived for selected organs and tumor lesions and absorbed radiation doses of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) in critical organs (e.g., kidneys, liver) will be calculated.	During serial PET/CT scans taken on Day 1 at the following timepoints at 0.5 hour ± 10 minutes, 1 hour ±10 minutes, 2 hours ± 15 minutes, 4 to 6 hours, and 24 hours ± 4 hours post study intervention administration.
Primary	Primary Part 1 - Optimal dose (radioactivity and mass dose) and imaging time window of 64Cu-LNTH-1363S	Optimal dose (radioactivity and mass dose) and imaging time window will be determined using image quality scores from blinded central reviews. Each patient will receive either 8 ± 1 mCi /~50 µg or 8 ± 1 mCi/~90 µg of 64Cu-LNTH-1363S. The raw data of each patient PET scan will be re-processed using a computer program to simulate scans of the same patient with lower injected activities (6 and 4 mCi).	During serial PET/CT scans taken on Day 1 at the following timepoints at 0.5 hour ± 10 minutes, 1 hour ±10 minutes, 2 hours ± 15 minutes, 4 to 6 hours, and 24 hours ± 4 hours post study intervention administration.
Primary	Primary Part 2 - Correlation of 64Cu-LNTH-1363S biodistribution with Immunohistochemistry FAP expression	Correlation of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) biodistribution with FAP expression by IHC (SUVmean and SUVmax vs IHC score) and compare to circulating FAP in blood as analyzed by ELISA method.	Post surgery tissue collection to end of study
Secondary	Secondary Parts 1 and 2 Safety and Tolerability	Safety and tolerability profile of 64Cu-LNTH-1363S in patients with sarcoma and GITs based on: Frequency and severity of adverse events (AEs) and serious AEs (SAEs) measured by Common Terminology Criteria for AEs (CTCAE) v5.0 or higher.; Changes in vital signs; Changes in laboratory parameters; Changes in electrocardiogram (ECG)parameters; • Exposure-response relationships: Relationship of AEs to exposure (dose and concentrations).	Part1: From IP administration until the Day 7 (± 1 day) telephone follow up. Part 2: From time of IP administration to until post-surgery IHC sample collection.
Secondary	Secondary Part 1 FAP expression profile of 64Cu-LNTH-1363S in patients with sarcoma	Correlation of 64Cu-LNTH-1363S biodistribution with FAP expression by immunohistochemistry (IHC) (SUVmean and SUVmax vs IHC score) and compare to circulating FAP in blood as analyzed by ELISA method.	From Day 1 until the end of the Scheduled Surgery: IHC sample collection
Secondary	Secondary Part 1 and Part 2 Cardiac Safety	Monitor cardiac safety and look for signals suggesting a concentration-response relationship of 64Cu-LNTH-1363S for QT/corrected QT interval (QTc) prolongation.	Continuous ECG monitoring at Visit 2
Secondary	Secondary Part 2 Validate optimal radioactivity in patients with sarcoma or GIT cancer	Validate optimal radioactivity in patients with sarcoma or GIT cancer, if the optimal radioactivity determined in Part 1 is less than 8 ± 1 mCi. Validation to be completed on image quality score of first 6 patients, if optimal radioactivity determined in Part 1 is less than 8 ± 1 mCi.	From start of Part 2 to 6 patients enrolled with qualifying imaging